74:
mount an immune response against the recipient's lymphoid tissue. These donor lymphocytes engraft, recognize recipient cells as foreign and mount an immune response against recipient tissues. Donor lymphocytes are usually identified as foreign and destroyed by the recipient's immune system. However,
79:
type is similar (as can occur in directed donations from first-degree relatives), the recipient's immune system is not able to destroy the donor lymphocytes. This can result in transfusion associated graft-versus-host disease. This is in contrast with organ/tissue transplant associated
593:
578:
225:
The incidence of TA-GvHD in immunocompromised patients receiving blood transfusions is estimated to be 0.1–1.0%, and mortality around 80–90%. Mortality is higher in TA-GvHD than in GvHD associated with
1162:
179:
of the lymphocyte-containing blood components such as red blood cells, platelets and granulocytes. Irradiated blood components should be issued in the following situations:
879:
636:
96:
occurring in other settings, such as bone marrow transplantation. TA-GvHD can develop two days to six weeks after the transfusion. Typical symptoms include:
874:
884:
757:
161:
analysis of the circulating lymphocytes. This testing can identify circulating lymphocytes with a different HLA type than the tissue cells of the host.
900:
869:
895:
385:"Transfusion associated graft versus host disease following whole blood transfusion from an unrelated donor in an immunocompetent patient"
217:
Treatment is supportive. No available form of therapy has proven effective in treating TA-GvHD and it is fatal in more than 90% of cases.
629:
452:
912:
1167:
1172:
697:
622:
947:
801:
817:
227:
535:
117:
1027:
1022:
987:
967:
922:
864:
93:
81:
834:
17:
844:
992:
1141:
1092:
1072:
719:
262:
158:
76:
1116:
1062:
1037:
957:
935:
682:
1102:
1057:
962:
238:
are of donor origin (in autotransplant) and therefore the immune reaction is not directed against them.
1067:
982:
972:
854:
796:
675:
649:
147:
1052:
1042:
692:
597:
164:
In 2023, the first case of fetal-induced GvHD was reported in the New
England Journal of Medicine.
1082:
108:
75:
in situations where the recipient is severely immunocompromised, or when the donor and recipient
1136:
1131:
1017:
714:
645:
522:
494:
458:
448:
414:
329:
302:
67:
46:
614:
231:
839:
786:
752:
726:
404:
396:
294:
245:
in TA-GvHD are infections and hemorrhages secondary to pancytopenia and liver dysfunction.
1126:
940:
707:
702:
242:
548:
1012:
907:
822:
782:
747:
409:
384:
602:
482:
1156:
997:
790:
657:
431:
1046:
687:
507:
143:
123:
112:
1002:
829:
665:
235:
176:
536:"Transfusion associated graft vs. host disease and irradiated blood components"
321:
263:"Complications of Transfusion: Transfusion Medicine: Merck Manual Professional"
930:
742:
587:
400:
298:
51:
462:
1007:
889:
778:
173:
526:
498:
418:
333:
306:
200:
Components that are HLA matched, or directed donations from a family member
539:
762:
670:
570:
134:
Other symptoms can include cough, abdominal pain, dyspnea and vomiting.
1121:
1087:
1032:
582:
447:(18th ed.). Bethesda, Md.: American Association of Blood Banks.
188:
Prematurity, low birthweight, or erythroblastosis fetalis in newborns
154:
71:
1111:
1097:
1077:
102:
1106:
977:
952:
618:
84:, where matching HLA reduces the incident of the complication.
358:
197:
Patients undergoing hematopoietic stem cell transplantation
383:
Patel KK, Patel AK, Ranjan RR, Shah AP (September 2010).
194:
Certain hematologic malignancies (e.g. Hodgkin lymphoma)
150:, and electrolyte imbalance (when diarrhea is present).
443:
Fung MK, Grossman BJ, Hillyer CD, Westhoff CM (2014).
560:
389:
Indian
Journal of Hematology & Blood Transfusion
921:
853:
810:
771:
735:
656:
564:
45:
37:
32:
508:"Transfusion associated graft versus host disease"
506:Gupta A, Bansal D, Dass R, Das A (December 2004).
483:"Transfusion associated graft versus host disease"
157:of the affected skin or liver, and established by
432:A Case of Fetal-Induced Graft-versus-Host Disease
880:Transfusion-associated graft versus host disease
285:Savage WJ (June 2016). "Transfusion Reactions".
60:Transfusion-associated graft-versus-host disease
33:Transfusion-associated graft-versus-host-disease
18:Transfusion-associated graft versus host disease
328:. Treasure Island (FL): StatPearls Publishing.
70:, in which the immunologically competent donor
630:
8:
287:Hematology/Oncology Clinics of North America
875:Transfusion associated circulatory overload
487:Journal of Ayub Medical College, Abbottabad
359:"National Healthcare Safety Network (NHSN)"
206:Patients receiving granulocyte transfusions
1163:Complications of surgical and medical care
885:Febrile non-hemolytic transfusion reaction
758:International Society of Blood Transfusion
637:
623:
615:
561:
29:
408:
320:Vaillant AA, Modi P, Mohammadi O (2022).
92:The clinical presentation is the same as
254:
203:Patients receiving fludarabine therapy
870:Transfusion related acute lung injury
7:
353:
351:
349:
280:
278:
111:, which can progress to generalised
25:
913:Transfusion transmitted infection
153:TA-GvHD can be suspected from a
1:
534:Triulzi DJ (September 1992).
191:Congenital immunodeficiencies
802:Intraoperative blood salvage
142:Laboratory findings include
66:) is a rare complication of
818:Blood compatibility testing
481:Anwar M, Bhatti FA (2003).
322:"Graft Versus Host Disease"
228:bone marrow transplantation
146:, marrow aplasia, abnormal
1189:
118:toxic epidermal necrolysis
865:Transfusion hemosiderosis
401:10.1007/s12288-010-0028-0
299:10.1016/j.hoc.2016.01.012
185:Intrauterine transfusions
845:Monocyte monolayer assay
547:Kardon E (8 July 2022).
720:Granulocyte transfusion
549:"Transfusion Reactions"
234:lymphoid cells in the
1168:Transfusion reactions
855:Transfusion reactions
1173:Transfusion medicine
835:Kleihauer–Betke test
797:Exchange transfusion
676:Platelet transfusion
650:transfusion medicine
172:Prevention includes
923:Blood group systems
858:and adverse effects
693:Fresh frozen plasma
109:maculopapular rash
88:Signs and symptoms
1150:
1149:
727:Blood substitutes
715:White blood cells
646:Blood transfusion
612:
611:
521:(12): 1260–1264.
515:Indian Pediatrics
68:blood transfusion
57:
56:
27:Medical condition
16:(Redirected from
1180:
840:Antibody elution
787:plateletpheresis
753:Blood management
736:General concepts
639:
632:
625:
616:
562:
556:
543:
538:. Archived from
530:
512:
502:
467:
466:
445:Technical manual
440:
434:
429:
423:
422:
412:
380:
374:
373:
371:
370:
355:
344:
343:
341:
340:
317:
311:
310:
282:
273:
272:
270:
269:
259:
241:The most common
120:in extreme cases
30:
21:
1188:
1187:
1183:
1182:
1181:
1179:
1178:
1177:
1153:
1152:
1151:
1146:
941:Secretor status
917:
857:
849:
806:
767:
731:
708:Cryosupernatant
703:Cryoprecipitate
683:Red blood cells
652:
643:
613:
608:
607:
573:
559:
546:
533:
510:
505:
480:
476:
474:Further reading
471:
470:
455:
442:
441:
437:
430:
426:
382:
381:
377:
368:
366:
357:
356:
347:
338:
336:
319:
318:
314:
284:
283:
276:
267:
265:
261:
260:
256:
251:
243:causes of death
223:
215:
170:
140:
90:
28:
23:
22:
15:
12:
11:
5:
1186:
1184:
1176:
1175:
1170:
1165:
1155:
1154:
1148:
1147:
1145:
1144:
1139:
1134:
1129:
1124:
1119:
1114:
1109:
1100:
1095:
1090:
1085:
1080:
1075:
1070:
1065:
1060:
1055:
1050:
1040:
1035:
1030:
1025:
1020:
1015:
1010:
1005:
1000:
995:
990:
985:
980:
975:
970:
965:
960:
955:
950:
945:
944:
943:
933:
927:
925:
919:
918:
916:
915:
910:
908:Serum sickness
905:
904:
903:
898:
887:
882:
877:
872:
867:
861:
859:
851:
850:
848:
847:
842:
837:
832:
827:
826:
825:
823:Cross-matching
814:
812:
808:
807:
805:
804:
799:
794:
783:plasmapheresis
775:
773:
769:
768:
766:
765:
760:
755:
750:
748:Blood donation
745:
739:
737:
733:
732:
730:
729:
724:
723:
722:
712:
711:
710:
705:
700:
695:
685:
680:
679:
678:
668:
662:
660:
658:Blood products
654:
653:
644:
642:
641:
634:
627:
619:
610:
609:
606:
605:
590:
574:
569:
568:
566:
565:Classification
558:
557:
544:
542:on 2006-07-22.
531:
503:
477:
475:
472:
469:
468:
454:978-1563958885
453:
435:
424:
375:
345:
312:
293:(3): 619–634.
274:
253:
252:
250:
247:
222:
219:
214:
211:
210:
209:
208:
207:
204:
201:
198:
195:
192:
189:
186:
169:
166:
139:
136:
132:
131:
130:
129:
126:
121:
115:
105:
89:
86:
55:
54:
49:
43:
42:
39:
35:
34:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
1185:
1174:
1171:
1169:
1166:
1164:
1161:
1160:
1158:
1143:
1140:
1138:
1135:
1133:
1130:
1128:
1125:
1123:
1120:
1118:
1115:
1113:
1110:
1108:
1104:
1101:
1099:
1096:
1094:
1091:
1089:
1086:
1084:
1081:
1079:
1076:
1074:
1071:
1069:
1066:
1064:
1061:
1059:
1056:
1054:
1051:
1048:
1044:
1041:
1039:
1036:
1034:
1031:
1029:
1026:
1024:
1021:
1019:
1016:
1014:
1011:
1009:
1006:
1004:
1001:
999:
996:
994:
991:
989:
986:
984:
981:
979:
976:
974:
971:
969:
966:
964:
961:
959:
958:Chido-Rodgers
956:
954:
951:
949:
946:
942:
939:
938:
937:
934:
932:
929:
928:
926:
924:
920:
914:
911:
909:
906:
902:
899:
897:
894:
893:
891:
888:
886:
883:
881:
878:
876:
873:
871:
868:
866:
863:
862:
860:
856:
852:
846:
843:
841:
838:
836:
833:
831:
828:
824:
821:
820:
819:
816:
815:
813:
809:
803:
800:
798:
795:
792:
791:leukapheresis
788:
784:
780:
777:
776:
774:
770:
764:
761:
759:
756:
754:
751:
749:
746:
744:
741:
740:
738:
734:
728:
725:
721:
718:
717:
716:
713:
709:
706:
704:
701:
699:
696:
694:
691:
690:
689:
686:
684:
681:
677:
674:
673:
672:
669:
667:
664:
663:
661:
659:
655:
651:
647:
640:
635:
633:
628:
626:
621:
620:
617:
604:
600:
599:
595:
591:
589:
585:
584:
580:
576:
575:
572:
567:
563:
554:
550:
545:
541:
537:
532:
528:
524:
520:
516:
509:
504:
500:
496:
492:
488:
484:
479:
478:
473:
464:
460:
456:
450:
446:
439:
436:
433:
428:
425:
420:
416:
411:
406:
402:
398:
394:
390:
386:
379:
376:
364:
360:
354:
352:
350:
346:
335:
331:
327:
323:
316:
313:
308:
304:
300:
296:
292:
288:
281:
279:
275:
264:
258:
255:
248:
246:
244:
239:
237:
233:
229:
220:
218:
212:
205:
202:
199:
196:
193:
190:
187:
184:
183:
182:
181:
180:
178:
175:
167:
165:
162:
160:
156:
151:
149:
148:liver enzymes
145:
137:
135:
127:
125:
122:
119:
116:
114:
110:
107:erythematous
106:
104:
101:
100:
99:
98:
97:
95:
87:
85:
83:
78:
73:
72:T lymphocytes
69:
65:
61:
53:
50:
48:
44:
40:
36:
31:
19:
592:
577:
552:
540:the original
518:
514:
493:(3): 56–58.
490:
486:
444:
438:
427:
395:(3): 92–95.
392:
388:
378:
367:. Retrieved
365:. 2017-12-29
362:
337:. Retrieved
325:
315:
290:
286:
266:. Retrieved
257:
240:
230:, where the
224:
221:Epidemiology
216:
171:
163:
152:
144:pancytopenia
141:
133:
124:hepatomegaly
113:erythroderma
91:
63:
59:
58:
931:Blood types
830:Coombs test
666:Whole blood
363:www.cdc.gov
236:bone marrow
177:irradiation
38:Other names
1157:Categories
743:Blood bank
369:2018-09-18
339:2023-02-02
326:StatPearls
268:2009-02-09
249:References
168:Prevention
52:Hematology
948:Augustine
892:reaction
890:Hemolytic
779:Apheresis
671:Platelets
553:EMedicine
463:881812415
232:engrafted
213:Treatment
138:Diagnosis
47:Specialty
1073:Lutheran
978:Dombrock
763:ISBT 128
527:15623910
499:14727344
419:21886390
334:30855823
307:27113000
128:diarrhea
1112:Scianna
998:Gerbich
901:delayed
772:Methods
410:3002081
64:TA-GvHD
41:TA-GvHD
1023:Indian
968:Cromer
963:Colton
688:Plasma
525:
497:
461:
451:
417:
407:
332:
305:
155:biopsy
1142:Other
1068:Lewis
1058:Knops
1038:KANNO
983:Duffy
973:Diego
896:acute
811:Tests
603:999.8
588:T80.8
511:(PDF)
174:gamma
103:fever
1122:T-Tn
1107:RHAG
1105:and
1098:Raph
1093:P1PK
1053:Kidd
1043:Kell
1008:GLOB
993:FORS
953:CD59
698:PF24
648:and
598:9-CM
523:PMID
495:PMID
459:OCLC
449:ISBN
415:PMID
330:PMID
303:PMID
94:GvHD
82:GvHD
1127:Vel
1117:Sid
1083:MNS
1063:Lan
1033:JMH
1003:GIL
936:ABO
594:ICD
579:ICD
405:PMC
397:doi
295:doi
159:HLA
77:HLA
1159::
1137:Yt
1132:Xg
1103:Rh
1088:OK
1078:LW
1047:Xk
1028:JR
1018:Ii
1013:Hh
988:Er
789:,
785:,
601::
586::
583:10
551:.
519:41
517:.
513:.
491:15
489:.
485:.
457:.
413:.
403:.
393:26
391:.
387:.
361:.
348:^
324:.
301:.
291:30
289:.
277:^
1049:)
1045:(
793:)
781:(
638:e
631:t
624:v
596:-
581:-
571:D
555:.
529:.
501:.
465:.
421:.
399::
372:.
342:.
309:.
297::
271:.
62:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.